GlassScriptPhysician profile
Norman S Chazin
NPI 1710970553
$3,789.20
in general payments reported to CMS, 2019-2025
21 companies · $709 in 2025
The $709 reported for 2025 was more than what 84% of Forensic Psychiatry providers received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $719 · 2020: $175 · 2021: $181 · 2022: $538 · 2023: $642 · 2024: $825 · 2025: $709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,175.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $922.93 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $644.27 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $395.70 | 2020-2025 | Caplyta |
| Lundbeck LLC | $345.88 | 2019-2025 | Rexulti |
| Neuronetics, INC. | $278.84 | 2019-2023 | Neurostar Tms Therapy System |
| Alkermes, INC. | $228.66 | 2021-2025 | Lybalvi, Aristada |
| Allergan, INC. | $203.61 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $194.08 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $105.08 | 2019-2024 | Trintellix |
| Avanir Pharmaceuticals, INC. | $78.81 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $76.65 | 2019-2020 | |
| Bausch Health US, LLC | $56.42 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $52.02 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $45.48 | 2022-2023 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $43.84 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $29.46 | 2019 | |
| Indivior INC. | $26.21 | 2019 | |
| Axsome Therapeutics, INC. | $18.90 | 2025 | Auvelity |
| Braeburn INC. | $14.85 | 2024 | Brixadi |
| Almatica Pharma LLC | $14.77 | 2024 | Loreev Xr |
| Arbor Pharmaceuticals, INC. | $12.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Chazin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.